Rapport Therapeutics to Host 2025 Investor and Analyst Day
Rapport Therapeutics (NASDAQ: RAPP) has announced its first-ever Investor and Analyst Day, scheduled for June 2, 2025, in New York City. The event, to be held at Nasdaq MarketSite from 3:00 to 5:00 p.m. ET, will feature presentations from senior management focusing on the company's clinical programs, particularly the RAP-219 Phase 2a trial in refractory focal epilepsy.
A highlight of the event will be a fireside chat with Dr. Jacqueline A. French, a renowned epilepsy researcher from NYU Langone's Comprehensive Epilepsy Center and principal investigator of the RAP-219 trial. The event will be accessible via live and archived webcasts through the company's investor relations website.
Rapport Therapeutics (NASDAQ: RAPP) ha annunciato il suo primo Investor and Analyst Day, previsto per il 2 giugno 2025 a New York City. L'evento si terrà presso il Nasdaq MarketSite dalle 15:00 alle 17:00 ET e includerà presentazioni da parte del management senior, con un focus particolare sui programmi clinici dell'azienda, in particolare lo studio di fase 2a RAP-219 sull'epilessia focale refrattaria.
Uno dei momenti salienti sarà una conversazione informale con la Dott.ssa Jacqueline A. French, rinomata ricercatrice sull'epilessia presso il Comprehensive Epilepsy Center di NYU Langone e investigatrice principale dello studio RAP-219. L'evento sarà accessibile tramite webcast in diretta e registrati sul sito web delle relazioni con gli investitori dell'azienda.
Rapport Therapeutics (NASDAQ: RAPP) ha anunciado su primer Investor and Analyst Day, programado para el 2 de junio de 2025 en la ciudad de Nueva York. El evento, que se llevará a cabo en Nasdaq MarketSite de 3:00 a 5:00 p.m. ET, contará con presentaciones del equipo directivo centradas en los programas clínicos de la compañía, especialmente el ensayo de fase 2a RAP-219 en epilepsia focal refractaria.
Un momento destacado será una charla informal con la Dra. Jacqueline A. French, reconocida investigadora en epilepsia del Comprehensive Epilepsy Center de NYU Langone e investigadora principal del ensayo RAP-219. El evento será accesible mediante transmisiones en vivo y archivadas a través del sitio web de relaciones con inversionistas de la compañía.
Rapport Therapeutics (NASDAQ: RAPP)는 2025년 6월 2일 뉴욕시에서 최초의 투자자 및 애널리스트 데이를 개최한다고 발표했습니다. 이 행사는 Nasdaq MarketSite에서 동부 표준시 기준 오후 3시부터 5시까지 진행되며, 회사의 임상 프로그램, 특히 난치성 국소성 간질에 대한 RAP-219 2a상 시험에 대한 고위 경영진 발표가 포함됩니다.
행사의 하이라이트는 NYU Langone의 종합 간질 센터의 저명한 간질 연구자이자 RAP-219 시험의 책임 연구원인 Jacqueline A. French 박사와의 대화입니다. 이 행사는 회사의 투자자 관계 웹사이트를 통해 라이브 및 아카이브 웹캐스트로 시청할 수 있습니다.
Rapport Therapeutics (NASDAQ: RAPP) a annoncé sa toute première journée dédiée aux investisseurs et analystes, prévue le 2 juin 2025 à New York. L'événement se tiendra au Nasdaq MarketSite de 15h00 à 17h00 (heure de l'Est) et comprendra des présentations de la haute direction axées sur les programmes cliniques de la société, en particulier l'essai de phase 2a RAP-219 dans l'épilepsie focale réfractaire.
Un moment fort de la journée sera une discussion informelle avec la Dr Jacqueline A. French, chercheuse renommée en épilepsie au Comprehensive Epilepsy Center de NYU Langone et investigatrice principale de l'essai RAP-219. L'événement sera accessible via des webcasts en direct et archivés sur le site des relations investisseurs de la société.
Rapport Therapeutics (NASDAQ: RAPP) hat seinen allerersten Investor and Analyst Day angekündigt, der am 2. Juni 2025 in New York City stattfinden wird. Die Veranstaltung findet im Nasdaq MarketSite von 15:00 bis 17:00 Uhr ET statt und umfasst Präsentationen des oberen Managements mit Fokus auf die klinischen Programme des Unternehmens, insbesondere die RAP-219 Phase-2a-Studie bei refraktärer fokaler Epilepsie.
Ein Highlight der Veranstaltung wird ein Gespräch am Kamin mit Dr. Jacqueline A. French sein, einer renommierten Epilepsieforscherin vom Comprehensive Epilepsy Center der NYU Langone und Hauptprüferin der RAP-219-Studie. Die Veranstaltung wird über Live- und Archiv-Webcasts auf der Investor-Relations-Website des Unternehmens zugänglich sein.
- None.
- None.
BOSTON and SAN DIEGO, May 21, 2025 (GLOBE NEWSWIRE) -- Rapport Therapeutics, Inc. (Nasdaq: RAPP), a clinical-stage biotechnology company dedicated to the discovery and development of small molecule precision medicines for patients with neurological or psychiatric disorders, today announced it will host its inaugural Investor and Analyst Day on Monday, June 2, 2025, in New York City. The event will also be webcast live.
Rapport senior management will review the company’s clinical programs, with a focus on the RAP-219 Phase 2a trial in refractory focal epilepsy. The event will also feature a fireside chat with Dr. Jacqueline A. French—a globally recognized leader in epilepsy research, professor of Neurology at NYU Langone's Comprehensive Epilepsy Center, founder and director of the Epilepsy Study Consortium, and principal investigator of the RAP-219 Phase 2a trial.
Event Details:
Date: Monday, June 2, 2025
Time: 3:00 – 5:00 p.m. Eastern Time
Location: Nasdaq MarketSite, New York City
Live and archived webcasts of the presentation can be accessed by visiting ‘Events & Presentations’ in the Investors section on the Company's website at https://investors.rapportrx.com.
About Rapport Therapeutics
Rapport Therapeutics is a clinical-stage biotechnology company dedicated to discovering and developing small molecule precision medicines for patients with neurological or psychiatric disorders. The Company’s founders have made pioneering discoveries related to the function of receptor associated proteins (RAPs) in the brain. Their findings form the basis of Rapport’s RAP technology platform, which enables a differentiated approach to generate precision small molecule product candidates with the potential to overcome many limitations of conventional neurology drug discovery. Rapport’s precision neuroscience pipeline includes the Company’s lead investigational drug, RAP-219, designed to achieve neuroanatomical specificity through its selective targeting of a RAP expressed in only discrete regions of the brain. The Company is currently pursuing RAP-219 as a potential treatment for refractory focal epilepsy, bipolar mania and diabetic peripheral neuropathic pain. Additional preclinical and late-stage discovery stage programs are also underway, including targeting chronic pain and hearing disorders.
Contact
Julie DiCarlo
Head of Communications & IR, Rapport Therapeutics
jdicarlo@rapportrx.com
FAQ
When is Rapport Therapeutics (RAPP) hosting its 2025 Investor Day?
What will be discussed at RAPP's 2025 Investor Day?
How can investors access Rapport Therapeutics' 2025 Investor Day?
Who is the featured speaker at RAPP's 2025 Investor Day?
